Adhera Therapeutics (ATRX) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Marina Biotech, Inc.
Entity Central Index Key	737207
Trading Symbol	mrna
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,642,904
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash	$1,163	$1,824
Accounts receivable		500
Prepaid expenses and other current assets	139	192
Total current assets	1,302	2,516
Intangible assets	6,700	6,700
Other assets	45
Total assets	8,047	9,216
Current liabilities:
Accounts payable	581	687
Accrued payroll and employee benefits	218	183
Other accrued liabilities	1,058	1,072
Total current liabilities	1,857	1,942
Fair value liability for price adjustable warrants	7,496	9,225
Fair value of stock to be issued to settle liabilities		75
Deferred income tax liabilities	2,345	2,345
Total liabilities	11,698	13,587
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $.01 par value; 100,000 shares authorized, 1,200 shares of Series C convertible preferred stock issued and outstanding at December 31, 2014 and March 31, 2015 (liquidation preference of $6,000,000 December 31, 2014 and March 31, 2015)
Common stock, $0.006 par value; 180,000,000 shares authorized, 25,523,216 and 25,642,904 shares issued and outstanding at December 31, 2014 and March 31, 2015, respectively	154	153
Additional paid-in capital	333,569	333,264
Accumulated deficit	-337,374	-337,788
Total stockholders' deficit	-3,651	-4,371
Total liabilities and stockholders' deficit	$8,047	$9,216

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	25,642,904	25,523,216
Common stock, shares outstanding	25,642,904	25,523,216
Statement [Line Items]
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	100,000	100,000
Series C Convertible Preferred Stock ("Series C Stock")
Statement [Line Items]
Preferred stock, shares authorized	1,200
Preferred stock, shares issued	1,200	1,200
Preferred stock, shares outstanding	1,200	1,200
Preferred Stock, Liquidation Preference, Value	$6,000,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
Research and development	$254	$46
General and administrative	1,061	517
Total operating expenses	1,315	563
Loss from operations	-1,315	-563
Other income (expense):
Interest and other expense		-1,007
Change in fair value liability for price adjustable warrants	1,729	-5,314
Change in fair value of stock reserved for issuance to settle liabilities		-2,455
Gain on debt extinguishment		4
Gain on settled liabilities		257
Total other income (expense)	1,729	-8,515
Net income (loss) applicable to common stockholders	414	-9,078
Deemed dividend related to discount on beneficial conversion feature in Series C convertible preferred stock		-6,000
Net income (loss) applicable to common stockholders	$414	($15,078)
Net income (loss) per common share
Basic (in dollars per share)	$0.02	($0.70)
Diluted (in dollars per share)	($0.04)	($0.70)
Shares used in computing net income (loss) per share
Basic (in shares)	25,632	21,447
Diluted (in shares)	32,555	21,447

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating activities:
Net income (loss)	$414	($9,078)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash gain on debt extinguishment		-4
Non-cash interest expense		1,007
Non-cash gain on settlement of liabilities		-257
Compensation related to stock options and warrants	180	59
Changes in fair market value of liabilities
Stock reserved for issuance to settle liabilities		2,455
Price adjustable warrants	-1,729	5,314
Cash changes in assets and liabilities
Accounts receivable	500	5
Prepaid expenses and other assets	8	-9
Accounts payable	-106	-24
Accrued and other liabilities	71	-533
Net cash used in operating activities	-662	-1,065
Financing activities:
Proceeds from sales of Series C preferred shares and warrants, net		5,929
Cash payments on notes payable		-250
Insurance financing		-3
Proceeds from exercise of warrants for common stock	1
Net cash provided by financing activities	1	5,676
Net increase (decrease) in cash	-661	4,611
Cash and cash equivalents - January 1	1,824	909
Cash and cash equivalents - March 31	1,163	5,520
Supplemental disclosure of cash flow information and non-cash financing activities:
Cash paid for interest		83
Reclassification of fair value liability for price adjustable warrants exercised		1,862
Fair value of warrants issued to purchase common stock to settle liabilities	50
Issuance of common stock to settle liabilities	75	3,474
Debt conversion to common shares		1,479
Deemed dividend to Series C convertible preferred stockholders		$6,000

Business_Liquidity_and_Summary

Business, Liquidity and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business, Liquidity and Summary of Significant Accounting Policies	Note 1 — Business, Liquidity and Summary of Significant Accounting Policies
	Business
	Business
	We are a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. Our pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (“FAP”), for which we have received Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”), and preclinical programs for the treatment of type 1 myotonic dystrophy (“DM1”) and Duchenne muscular dystrophy (“DMD”).
	Since 2010, we have strategically acquired/in-licensed and further developed nucleic acid chemistry and delivery-related technologies in order to establish a novel and differentiated drug discovery platform. This platform allows us to distinguish ourselves from others in the nucleic acid therapeutics area in that we are the only company capable of creating a wide variety of therapeutics targeting coding and non-coding RNA via multiple mechanisms of action such as RNA interference (“RNAi”), messenger RNA translational inhibition, exon skipping, microRNA (“miRNA”) replacement, miRNA inhibition, and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. Our goal is to dramatically improve the lives of the patients and families affected by orphan diseases through either our own efforts or those of our collaborators and licensees.
	Liquidity
	The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At March 31, 2015, we had an accumulated deficit of approximately $337.4 million, $111.7 million of which has been accumulated since we focused on RNA therapeutics in June 2008. To the extent that sufficient funding is available, we will continue to incur losses as we continue our research and development (“R&D”) activities. In addition, we have had and will continue to have negative cash flows from operations. We have funded our losses primarily through the sale of common and preferred stock and warrants, revenue provided from our license agreements and, to a lesser extent, equipment financing facilities and secured loans. In 2014, we funded operations with a combination of the issuance of preferred stock and license-related revenues. At March 31, 2015, we had negative working capital of $0.6 million and $1.2 million in cash. Our resumed operating activities consume the majority of our cash resources.
	We believe that our current cash resources will enable us to fund our intended limited operations through September 2015. Our ability to execute our operating plan beyond September 2015 depends on our ability to obtain additional funding. The volatility in our stock price, as well as market conditions in general, could make it difficult for us to raise capital on favorable terms, or at all. If we fail to obtain additional capital when required, we may have to modify, delay or abandon some or all of our planned activities, or terminate our operations. We are currently pursuing both non-dilutive means of obtaining additional capital, primarily from existing and potential future licenses and partnerships, and dilutive means of obtaining additional capital, primarily through the offering of our equity and debt securities. However, there can be no assurance that we will be successful in such endeavors. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Basis of Preparation and Summary of Significant Accounting Policies
	Basis of Preparation — The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2014, included in our 2014 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results for the year ending December 31, 2015 or for any future period.
	Use of Estimates — The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Estimates having relatively higher significance include revenue recognition, stock-based compensation, valuation of warrants, valuation and estimated lives of identifiable intangible assets, impairment of long-lived assets, valuation of features embedded within note agreements and amendments, and income taxes. Actual results could differ from those estimates.
	Fair Value of Financial Instruments — We consider the fair value of cash, accounts receivable, accounts payable and accrued liabilities to not be materially different from their carrying value. These financial instruments have short-term maturities.
	We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
	Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.
	Our cash is subject to fair value measurement and value is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes using the Black-Scholes option pricing model (“Black-Scholes Model”) under various probability weighted scenarios, using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2014 and March 31, 2015:
					Level 1					Level 3
		Balance at			Quoted prices in			Level 2		Significant
		December 31,			active markets for			Significant other		unobservable
	(In thousands)	2014			identical assets			observable inputs		inputs
	Liabilities:
	Fair value liability for price adjustable warrants	$	9,225		$	-		$	-	$	9,225
	Fair value liability for shares to be issued		75			75			-		-
	Total liabilities at fair value	$	9,300		$	75		$	-	$	9,225
	7
					Level 1					Level 3
					Quoted prices in			Level 2		Significant
		Balance at			active markets for			Significant other		unobservable
	(In thousands)	31-Mar-15			identical assets			observable inputs		inputs
	Liabilities:
	Fair value liability for price adjustable warrants	$	7,496		$	-		$	-	$	7,496
	Total liabilities at fair value	$	7,496		$	-		$	-	$	7,496
	The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the three-month period ended March 31, 2015:
					Weighted average as of each measurement date
		Fair value
		liability for price											Contractual
		adjustable warrants			Exercise			Stock					life		Risk free
		(in thousands)			Price			Price		Volatility			(in years)		rate
	Balance at December 31, 2014	$	9,225		$	0.42		$	0.95		121	%		3.51		0.9	%
	Change in fair value included in statement of operations		(1,729	)
	Balance at March 31, 2015	$	7,496		$	0.42		$	0.64		110	%		2.42		0.66	%
	Net Income (Loss) per Common Share — Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of common stock equivalents (stock options, unvested restricted stock, warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. The following number of shares have been excluded from diluted net income (loss) since such inclusion would be anti-dilutive:
		Three Months Ended March 31,
		2014			2015
	Stock options outstanding		284,829			1,316,106
	Warrants		21,235,695			1,285,693
	Total		21,520,524			2,601,799
	The following is a reconciliation of basic and diluted net income (loss) per share:
		Three Months Ended March 31,
		2014			2015
	Net income (loss) – numerator basic	$	(15,078	)	$	414
	Change in fair value liability for price adjustable warrants		-			(1,729	)
	Net loss excluding change in fair value liability for price adjustable warrants	$	(15,078	)	$	(1,315	)
	Weighted average common shares outstanding – denominator basic		21,447			25,632
	Effect of price adjustable warrants		-			6,923
	Weighted average dilutive common shares outstanding		21,447			32,555
	Net income (loss) per common share – basic	$	(0.70	)	$	0.02
	Net income (loss) per common share – diluted	$	(0.70	)	$	(0.04	)
	Recently Issued Accounting Standards - In April 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2015-03, 'Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 is intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. This new guidance is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted. We are currently in the process of evaluating the impact of the adoption of this ASU on the financial statements.
	In January 2015, FASB issued ASU 2015-01 “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items”. This ASU removes the concept of an extraordinary item.  Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item.  If an event or transaction meets the criteria for extraordinary classification, an entity is required to segregate the extraordinary item from the results of ordinary operations and show the item separately in the income statement, net of tax, after income from continuing operations. The entity also is required to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item.  The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015.  Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 2 — Stockholders’ Deficit
	Preferred Stock — Our board of directors has the authority, without action by the stockholders, to designate and issue up to 100,000 shares of preferred stock in one or more series and to designate the rights, preferences and privileges of each series, any or all of which may be greater than the rights of our common stock. We have designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series B Preferred or Series A Preferred are outstanding. In March 2014, we designated 1,200 shares of Series C Convertible Preferred Stock (“Series C Preferred”).
	In March 2014, we entered into a Securities Purchase Agreement with certain investors pursuant to which we sold 1,200 shares of Series C Preferred, and price adjustable warrants to purchase up to 6.0 million shares of our common stock at an exercise price of $0.75 per share, for an aggregate purchase price of $6.0 million. Each share of Series C Preferred has a stated value of $5,000 per share and is convertible into shares of common stock at a conversion price of $0.75 per share. The Series C Preferred is initially convertible into an aggregate of 8,000,000 shares of our common stock, subject to certain limitations and adjustments, has no stated dividend rate, is not redeemable and has voting rights on an as-converted basis.
	To account for the issuance of the Series C Preferred and warrants, we first assessed the terms of the warrants and determined that, due to certain anti-dilution provisions, they should be recorded as derivative liabilities. We determined the fair value of the warrants on the issuance date and recorded a liability of $6.5 million. Since the fair value of the warrants exceed the total proceeds received of $6.0 million, we recorded a loss of $0.5 million upon issuance, which is included in the change in fair value of price adjustable warrants in the consolidated statements of operations. The discount of $6.0 million on the Series C Preferred resulting from the allocation of the entire proceeds to the warrant was accreted as a dividend on the Series C Preferred through the earliest conversion date, which was immediately. The Series C Preferred dividend of $6.0 million was recorded to additional paid-in capital and as a deemed dividend on the Series C Preferred in determining net loss applicable to common stock holders in the consolidated statements of operations. We incurred $0.07 million of stock issuance costs in conjunction with the Series C Preferred, which were netted against the proceeds.
	Common Stock — Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of our common stock. Subject to the rights of the holders of any class of our capital stock having any preference or priority over our common stock, the holders of our common stock are entitled to receive dividends that are declared by our board of directors out of legally available funds. In the event of our liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in our net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. Our common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of our common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights. Our common stock currently trades on the OTCQB tier of the OTC Markets.
	In January 2015, we issued 0.12 million shares with a value of $0.075 million to Novosom as the equity component owed under our December 2014 license agreement with MiNA Therapeutics.
	Warrants — In January 2015, an investor exercised 2,500 warrants at an exercise price of $0.28 prior to warrant expiry.
	In December 2013, we issued warrants to purchase up to 0.10 million shares of our common stock to a consultant who is our interim chief financial officer. These warrants vest over two years, have a fixed strike price of $0.48, and expire in December 2023. The total stock-based expense related to the warrants that vested during the three months ended March 31, 2015 amounted to $0.01 million. At March 31, 2015, we had $0.03 million of total unrecognized compensation expense related to unvested warrants. We expect to recognize this cost by end of 2015.
	In January and February 2015, we issued warrants to purchase up to an aggregate of 0.064 million shares to a vendor providing scientific and development consulting services to our company. The fair value of these warrants at issuance was $0.05 million and was accrued at December 31, 2014.
	The following table summarizes warrant activity during the three months ended March 31, 2015:
		Warrant			Weighted
		Shares			Average
					Exercise Price
	Outstanding, December 31, 2014		21,212,813		$	1.19
	Exercised warrants		(2,500	)		0.28
	Warrants issued		66,717			0.75
	Outstanding, March 31, 2015		21,277,030		$	1.19
	Expiring in 2015		285,345
	Expiring in 2016		6,000,000
	Expiring in 2017		7,235,622
	Expiring thereafter		7,756,063

Stock_Incentive_Plans

Stock Incentive Plans	3 Months Ended
	Mar. 31, 2015
Stock Incentive Plans [Abstract]
Stock Incentive Plans	Note 3 — Stock Incentive Plans
	Stock-based Compensation. Certain option and share awards provide for accelerated vesting if there is a change in control as defined in the applicable plan and certain employment agreements. The following table summarizes stock-based compensation expense:
		Three months ended March 31,
	(In thousands)	2014		2015
	Research and development	$	10	$	26
	General and administrative		10		145
	Total	$	20	$	171
	Stock Options — Stock option activity was as follows:
		Options Outstanding
		2015
		Shares		Weighted Average
				Exercise Price
	Outstanding, January 1		1,084,106	$	5.52
	Options Issued		232,000	$	0.63
	Outstanding, March 31		1,316,106	$	4.66
	Exercisable, March 31		293,856	$	17.34
	The following table summarizes additional information on our stock options outstanding at March 31, 2015:
		Options Outstanding						Options Exercisable
	Range of Exercise	Number		Weighted-average		Weighted-average		Number		Weighted-
	Prices	Outstanding		Remaining		Exercise Price		Exercisable		average
				Contractual Life						Exercise Price
				(Years)
	$0.63 - $0.82		252,000		4.75	$	0.65		126,000	$	0.65
	$0.83 - $1.07		1,019,000		8.25		1.07		124,000		1.07
	$1.08 - $2.20		2,500		6.44		2.2		1,250		2.2
	$2.21 - $50.00		10,500		3.2		47.6		10,500		47.6
	$50.01 - $100.00		10,500		3.2		87.6		10,500		87.6
	$100.01 - $200.00		16,000		3.2		141.35		16,000		141.35
	$200.01 - $526.40		5,606		3.17		213.63		5,606		213.63
	Totals		1,316,106		7.41	$	4.66		293,856	$	17.34
	Weighted-Average Exercisable Remaining Contractual Life										4.41
	In January 2015, we issued options to purchase up to an aggregate of 152,000 shares of our common stock to non-employee members of our board of directors at an exercise price of $0.635 per share as the annual grant to such directors for their service on our board of directors during 2015, and we issued options to purchase up to an aggregate of 80,000 shares of our common stock to the members of our scientific advisory board at an exercise price of $0.63 per share as the annual grant to such persons for their service on our scientific advisory board during 2015.
	At March 31, 2015, we had $0.75 million of total unrecognized compensation expense related to unvested stock options. We expect to recognize this cost over a weighted average period of 2.2 years.
	At March 31, 2015, the intrinsic value of options outstanding or exercisable was zero as there were no options outstanding with an exercise price less than $0.58, the per share closing market price of our common stock at that date. No options were exercised during the three months ended March 31, 2015.

Intellectual_Property_and_Coll

Intellectual Property and Collaborative Agreements	3 Months Ended
	Mar. 31, 2015
Intellectual Property and Contractual Agreements [Abstract]
Intellectual Property and Collaborative Agreements	Note 4 — Intellectual Property and Collaborative Agreements
	Novosom — In July 2010, we entered into an agreement pursuant to which we acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. In January 2015, we paid Novosom $0.08 million cash and issued 0.12 million shares of common stock valued at $0.075 million for amounts due related to the MiNA license signed in December 2014.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 5 — Commitments and Contingencies
	Contingencies — We are subject to various legal proceedings and claims that arise in the ordinary course of business. Our management currently believes that resolution of such legal matters will not have a material adverse impact on our consolidated financial position, results of operations or cash flows.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 6 — Subsequent Events
	On May 11, 2015, we amended the SMARTICLES licensing agreement that we entered into in December 2011 with Mirna Therapeutics, Inc. to allow for prepayment by Mirna to us of a future milestone. On May 12, 2015, Mirna paid $400,000 to satisfy that future milestone obligation.

Business_Liquidity_and_Summary1

Business, Liquidity and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation — The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2014, included in our 2014 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results for the year ending December 31, 2015 or for any future period.
Use of Estimates	Use of Estimates — The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Estimates having relatively higher significance include revenue recognition, stock-based compensation, valuation of warrants, valuation and estimated lives of identifiable intangible assets, impairment of long-lived assets, valuation of features embedded within note agreements and amendments, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — We consider the fair value of cash, accounts receivable, accounts payable and accrued liabilities to not be materially different from their carrying value. These financial instruments have short-term maturities.
	We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
	Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.
	Our cash is subject to fair value measurement and value is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. We measure the liability for price adjustable warrants and certain features embedded in notes using the Black-Scholes option pricing model (“Black-Scholes Model”) under various probability weighted scenarios, using Level 3 inputs. The following tables summarize our liabilities measured at fair value on a recurring basis as of December 31, 2014 and March 31, 2015:
					Level 1					Level 3
		Balance at			Quoted prices in			Level 2		Significant
		December 31,			active markets for			Significant other		unobservable
	(In thousands)	2014			identical assets			observable inputs		inputs
	Liabilities:
	Fair value liability for price adjustable warrants	$	9,225		$	-		$	-	$	9,225
	Fair value liability for shares to be issued		75			75			-		-
	Total liabilities at fair value	$	9,300		$	75		$	-	$	9,225
					Level 1					Level 3
					Quoted prices in			Level 2		Significant
		Balance at			active markets for			Significant other		unobservable
	(In thousands)	31-Mar-15			identical assets			observable inputs		inputs
	Liabilities:
	Fair value liability for price adjustable warrants	$	7,496		$	-		$	-	$	7,496
	Total liabilities at fair value	$	7,496		$	-		$	-	$	7,496
	The following presents activity of the fair value liability of price adjustable warrants determined by Level 3 inputs for the three-month period ended March 31, 2015:
					Weighted average as of each measurement date
		Fair value
		liability for price											Contractual
		adjustable warrants			Exercise			Stock					life		Risk free
		(in thousands)			Price			Price		Volatility			(in years)		rate
	Balance at December 31, 2014	$	9,225		$	0.42		$	0.95		121	%		3.51		0.9	%
	Change in fair value included in statement of operations		(1,729	)
	Balance at March 31, 2015	$	7,496		$	0.42		$	0.64		110	%		2.42		0.66	%
Net Income (Loss) per Common Share	Net Income (Loss) per Common Share — Basic net income (loss) per common share is computed by dividing the netincome (loss) by the weighted average number of common shares outstanding during the period. Dilutednet income (loss) per shareincludesthe effect of common stock equivalents (stock options, unvested restricted stock, warrants)when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. The following number of shares have been excluded from diluted netincome (loss) since such inclusion would be anti-dilutive:
		Three Months Ended March 31,
		2014			2015
	Stock options outstanding		284,829			1,316,106
	Warrants		21,235,695			1,285,693
	Total		21,520,524			2,601,799
	The following is a reconciliation ofbasic and diluted net income (loss) per share:
		Three Months Ended March 31,
		2014			2015
	Net income (loss) – numerator basic	$	(15,078	)	$	414
	Change in fair value liability for price adjustable warrants		-			(1,729	)
	Net loss excluding change in fair value liability for price adjustable warrants	$	(15,078	)	$	(1,315	)
	Weighted average common shares outstanding – denominator basic		21,447			25,632
	Effect of price adjustable warrants		-			6,923
	Weighted average dilutive common shares outstanding		21,447			32,555
	Net income (loss) per common share – basic	$	(0.70	)	$	0.02
	Net income (loss) per common share – diluted	$	(0.70	)	$	(0.04	)
Recently Issued Accounting Standards	Recently Issued Accounting Standards - In April 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2015-03, 'Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 is intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. This new guidance is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted. We are currently in the process of evaluating the impact of the adoption of this ASU on the financial statements.
	In January 2015, FASB issued ASU 2015-01 “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items”. This ASU removes the concept of an extraordinary item. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. If an event or transaction meets the criteria for extraordinary classification, an entity is required to segregate the extraordinary item from the results of ordinary operations and show the item separately in the income statement, net of tax, after income from continuing operations. The entity also is required to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption.

Business_Liquidity_and_Summary2

Business, Liquidity and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of liabilities measured at fair value on a recurring basis					Level 1					Level 3
		Balance at			Quoted prices in			Level 2		Significant
		December 31,			active markets for			Significant other		unobservable
	(In thousands)	2014			identical assets			observable inputs		inputs
	Liabilities:
	Fair value liability for price adjustable warrants	$	9,225		$	-		$	-	$	9,225
	Fair value liability for shares to be issued		75			75			-		-
	Total liabilities at fair value	$	9,300		$	75		$	-	$	9,225
					Level 1					Level 3
					Quoted prices in			Level 2		Significant
		Balance at			active markets for			Significant other		unobservable
	(In thousands)	31-Mar-15			identical assets			observable inputs		inputs
	Liabilities:
	Fair value liability for price adjustable warrants	$	7,496		$	-		$	-	$	7,496
	Total liabilities at fair value	$	7,496		$	-		$	-	$	7,496
Schedule of fair value liability of price adjustable warrants determined by Level 3					Weighted average as of each measurement date
		Fair value
		liability for price											Contractual
		adjustable warrants			Exercise			Stock					life		Risk free
		(in thousands)			Price			Price		Volatility			(in years)		rate
	Balance at December 31, 2014	$	9,225		$	0.42		$	0.95		121	%		3.51		0.9	%
	Change in fair value included in statement of operations		(1,729	)
	Balance at March 31, 2015	$	7,496		$	0.42		$	0.64		110	%		2.42		0.66	%
Schedule of anti-dilutive securities		Three Months Ended March 31,
		2014			2015
	Stock options outstanding		284,829			1,316,106
	Warrants		21,235,695			1,285,693
	Total		21,520,524			2,601,799
Schedule of reconciliation of diluted weighted average shares outstanding
		Three Months Ended March 31,
		2014			2015
	Net income (loss) – numerator basic	$	(15,078	)	$	414
	Change in fair value liability for price adjustable warrants		-			(1,729	)
	Net loss excluding change in fair value liability for price adjustable warrants	$	(15,078	)	$	(1,315	)
	Weighted average common shares outstanding – denominator basic		21,447			25,632
	Effect of price adjustable warrants		-			6,923
	Weighted average dilutive common shares outstanding		21,447			32,555
	Net income (loss) per common share – basic	$	(0.70	)	$	0.02
	Net income (loss) per common share – diluted	$	(0.70	)	$	(0.04	)

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity [Abstract]
Schedule of warrant activity		Warrant			Weighted
		Shares			Average
					Exercise Price
	Outstanding, December 31, 2014		21,212,813		$	1.19
	Exercised warrants		(2,500	)		0.28
	Warrants issued		66,717			0.75
	Outstanding, March 31, 2015		21,277,030		$	1.19
	Expiring in 2015		285,345
	Expiring in 2016		6,000,000
	Expiring in 2017		7,235,622
	Expiring thereafter		7,756,063

Stock_Incentive_Plans_Tables

Stock Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2015
Stock Incentive Plans [Abstract]
Schedule of stock-based compensation expense		Three months ended March 31,
	(In thousands)	2014		2015
	Research and development	$	10	$	26
	General and administrative		10		145
	Total	$	20	$	171
Schedule of stock option activity		Options Outstanding
		2015
		Shares		Weighted Average
				Exercise Price
	Outstanding, January 1		1,084,106	$	5.52
	Options Issued		232,000	$	0.63
	Outstanding, March 31		1,316,106	$	4.66
	Exercisable, March 31		293,856	$	17.34
Schedule of summary of additional information on stock options outstanding		Options Outstanding						Options Exercisable
	Range of Exercise	Number		Weighted-average		Weighted-average		Number		Weighted-
	Prices	Outstanding		Remaining		Exercise Price		Exercisable		average
				Contractual Life						Exercise Price
				(Years)
	$0.63 - $0.82		252,000		4.75	$	0.65		126,000	$	0.65
	$0.83 - $1.07		1,019,000		8.25		1.07		124,000		1.07
	$1.08 - $2.20		2,500		6.44		2.2		1,250		2.2
	$2.21 - $50.00		10,500		3.2		47.6		10,500		47.6
	$50.01 - $100.00		10,500		3.2		87.6		10,500		87.6
	$100.01 - $200.00		16,000		3.2		141.35		16,000		141.35
	$200.01 - $526.40		5,606		3.17		213.63		5,606		213.63
	Totals		1,316,106		7.41	$	4.66		293,856	$	17.34
	Weighted-Average Exercisable Remaining Contractual Life										4.41

Business_Liquidity_and_Summary3

Business, Liquidity and Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Liabilities:
Fair value liability for price adjustable warrants	$7,496	$9,225
Fair value liability for shares to be issued		75
Fair value on recurring basis
Liabilities:
Fair value liability for price adjustable warrants	7,496	9,225
Fair value liability for shares to be issued		75
Total liabilities at fair value	7,496	9,300
Fair value on recurring basis | Level 1 Quoted prices in active markets for identical assets
Liabilities:
Fair value liability for price adjustable warrants
Fair value liability for shares to be issued		75
Total liabilities at fair value		75
Fair value on recurring basis | Level 2 Significant other observable inputs
Liabilities:
Fair value liability for price adjustable warrants
Fair value liability for shares to be issued
Total liabilities at fair value
Fair value on recurring basis | Level 3 Significant unobservable inputs
Liabilities:
Fair value liability for price adjustable warrants	7,496	9,225
Fair value liability for shares to be issued
Total liabilities at fair value	$7,496	$9,225

Business_Liquidity_and_Summary4

Business, Liquidity and Summary of Significant Accounting Policies (Details 1) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Fair value liability for price adjustable warrants
Balance at December 31, 2014	$9,225
Change in fair value included in statement of operations	-1,729
Balance at March 31, 2015	7,496
Fair Value Liability For Price Adjustable Warrants | Level 3 Significant unobservable inputs
Fair value liability for price adjustable warrants
Balance at December 31, 2014	9,225
Change in fair value included in statement of operations	-1,729
Balance at March 31, 2015	$7,496	$9,225
Exercise Price
Balance at December 31, 2014	$0.42
Balance at March 31, 2015	$0.42	$0.42
Stock Price
Balance at December 31, 2014	$0.95
Balance at March 31, 2015	$0.64	$0.95
Volatility
Balance at December 31, 2014	121.00%
Balance at March 31, 2015	110.00%	121.00%
Contractual life (in years)
Contractual life (in years)	2 years 5 months 1 day	3 years 6 months 4 days
Risk free rate
Balance at December 31, 2014	0.90%
Balance at March 31, 2015	0.66%	0.90%

Business_Liquidity_and_Summary5

Business, Liquidity and Summary of Significant Accounting Policies (Details 2)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	2,601,799	21,520,524
Stock options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,316,106	284,829
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,285,693	21,235,695

Business_Liquidity_and_Summary6

Business, Liquidity and Summary of Significant Accounting Policies (Details 3) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income (loss) - numerator basic	$414	($15,078)
Change in fair value liability for price adjustable warrants	-1,729
Net loss excluding change in fair value liability for price adjustable warrants	($1,315)	($15,078)
Weighted average common shares outstanding - denominator basic	25,632	21,447
Effect of price adjustable warrants	6,923
Weighted average dilutive common shares outstanding	32,555	21,447
Net income (loss) per common share - basic (in dollars per share)	$0.02	($0.70)
Net income (loss) per common share - diluted (in dollars per share)	($0.04)	($0.70)

Business_Liquidity_and_Summary7

Business, Liquidity and Summary of Significant Accounting Policies (Detail Textuals) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2008
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	($337,374,000)	($337,788,000)			($111,700,000)
Working capital	-600,000
Cash	$1,163,000	$1,824,000	$5,520,000	$909,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Warrant Shares
Outstanding, December 31, 2014	21,212,813
Warrants issued	66,717
Outstanding, March 31, 2015	21,277,030
Expiring in 2015	285,345
Expiring in 2016	6,000,000
Expiring in 2017	7,235,622
Expiring thereafter	7,756,063
Weighted average exercise price
Number of warrants exercised	2,500
Exercised warrants	$0.28
Outstanding, March 31, 2015	$1.19
Warrants issued	$0.75
Outstanding, December 31, 2014	$1.19

Stockholders_Equity_Preferred_

Stockholders' Equity (Preferred Stock) (Detail Textuals) (USD $)	1 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Derivative Liability		$6.50
Amount of loss upon issuance		0.5
Class of Stock [Line Items]
Preferred stock, shares authorized		100,000	100,000
Number of warrants called by common stock aggregate purchase price	6,000,000
Proceeds from sales of Series C preferred shares and warrants, net	6
Exercise price of warrants		$1.19	$1.19
Series A Junior Participating Preferred Stock ("Series A Preferred")
Class of Stock [Line Items]
Shares issued during period		90,000
Series B Preferred Stock ("Series B Preferred")
Class of Stock [Line Items]
Shares issued during period		1,000
Series C Convertible Preferred Stock ("Series C Stock")
Class of Stock [Line Items]
Preferred stock, shares authorized		1,200
Shares issued during period	1,200
Number of warrants called by common stock aggregate purchase price	6,000,000
Conversion price per dollar of stated value	$0.75
Proceeds from sales of Series C preferred shares and warrants, net	6
Stated value per share of preferred stock	$5,000
Exercise price of warrants	$0.75
Shares issued upon conversion	8,000,000
Stock issuance costs		$0.07

Stockholders_Equity_Common_Sto

Stockholders' Equity (Common Stock) (Detail Textuals 1) (USD $)	3 Months Ended	1 Months Ended
In Thousands, except Share data in Millions, unless otherwise specified	Mar. 31, 2015	Jan. 31, 2015
Stockholders' Equity [Abstract]
Number of voting right	one vote
Novosom | December 2014 license agreement with MiNA Therapeutics
Stockholders Equity Note [Line Items]
Number of common stock issued for settlement		0.12
Amount pledged to issue common stock		$75

Stockholders_Equity_Warrants_D

Stockholders' Equity (Warrants) (Detail Textuals 2) (USD $)	3 Months Ended		1 Months Ended	12 Months Ended	2 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 31, 2015	Dec. 31, 2013	Feb. 28, 2015	Dec. 31, 2014
Stockholders Equity Note [Line Items]
Number of warrants called by common stock		6,000,000
Number of warrants exercised	2,500
Exercise price of warrants	$1.19					$1.19
Fair value of warrants issuance	($1,729,000)	$5,314,000
Stock-based expense related to warrants	171,000	20,000
Warrants
Stockholders Equity Note [Line Items]
Number of warrants exercised			2,500
Exercise price of warrants			$0.28
Stock-based expense related to warrants	10,000
Unrecognized compensation cost related to unvested warrants	30,000
Warrants | Consultant
Stockholders Equity Note [Line Items]
Number of warrants called by common stock				100,000
Exercise price of warrants				$0.48
Warrants vesting period				2 years
Warrants | Vendor
Stockholders Equity Note [Line Items]
Number of warrants called by common stock					64,000
Fair value of warrants issuance					$50,000

Stock_Incentive_Plans_StockBas

Stock Incentive Plans (Stock-Based Compensation Expense) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$171	$20
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	26	10
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$145	$10

Stock_Incentive_Plans_Stock_Op

Stock Incentive Plans (Stock Option Activity) (Detail 1) (USD $)	3 Months Ended
	Mar. 31, 2015
Shares
Outstanding on January 1	1,084,106
Options Issued	232,000
Outstanding, March 31	1,316,106
Exercisable, March 31	293,856
Weighted Average Exercise Price
Outstanding on January 1	$5.52
Options Issued	$0.63
Outstanding, March 31	$4.66
Exercisable, March 31	$17.34

Recovered_Sheet1

Stock Incentive Plans (Stock options outstanding) (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number Outstanding	1,316,106	1,084,106
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	7 years 4 months 28 days
Options Outstanding, Weighted Average Exercise Price	$4.66	$5.52
Options Exercisable, Number Exercisable	293,856
Options Exercisable, Weighted Average Exercise Price	$17.34
Options Outstanding, Weighted-Average Remaining Contractual Life, Exercisable (Years)	4 years 4 months 28 days
Stock options | $0.63 - $0.82
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$0.63
Upper range of price	$0.82
Options Outstanding, Number Outstanding	252,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	4 years 9 months
Options Outstanding, Weighted Average Exercise Price	$0.65
Options Exercisable, Number Exercisable	126,000
Options Exercisable, Weighted Average Exercise Price	$0.65
Stock options | $0.83 - $1.07
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$0.83
Upper range of price	$1.07
Options Outstanding, Number Outstanding	1,019,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	8 years 3 months
Options Outstanding, Weighted Average Exercise Price	$1.07
Options Exercisable, Number Exercisable	124,000
Options Exercisable, Weighted Average Exercise Price	$1.07
Stock options | $1.08 - $2.20
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$1.08
Upper range of price	$2.20
Options Outstanding, Number Outstanding	2,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	6 years 5 months 9 days
Options Outstanding, Weighted Average Exercise Price	$2.20
Options Exercisable, Number Exercisable	1,250
Options Exercisable, Weighted Average Exercise Price	$2.20
Stock options | $2.21 - $50.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$2.21
Upper range of price	$50
Options Outstanding, Number Outstanding	10,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	3 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price	$47.60
Options Exercisable, Number Exercisable	10,500
Options Exercisable, Weighted Average Exercise Price	$47.60
Stock options | $50.01 - $100.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$50.01
Upper range of price	$100
Options Outstanding, Number Outstanding	10,500
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	3 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price	$87.60
Options Exercisable, Number Exercisable	10,500
Options Exercisable, Weighted Average Exercise Price	$87.60
Stock options | $100.01 - $200.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$100.01
Upper range of price	$200
Options Outstanding, Number Outstanding	16,000
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	3 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price	$141.35
Options Exercisable, Number Exercisable	16,000
Options Exercisable, Weighted Average Exercise Price	$141.35
Stock options | $200.01 - $526.40
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Lower range of price	$200.01
Upper range of price	$526.40
Options Outstanding, Number Outstanding	5,606
Options Outstanding, Weighted-Average Remaining Contractual Life (Years)	3 years 2 months 1 day
Options Outstanding, Weighted Average Exercise Price	$213.63
Options Exercisable, Number Exercisable	5,606
Options Exercisable, Weighted Average Exercise Price	$213.63

Stock_Incentive_Plans_Detail_T

Stock Incentive Plans (Detail Textuals) (USD $)	3 Months Ended	1 Months Ended
	Mar. 31, 2015	Jan. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase	232,000
Options Issued	$0.63
Board of directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase		152,000
Options Issued		$0.64
Board of directors | Subsequent event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchase		80,000
Options Issued		$0.63

Stock_Incentive_Plans_Detail_T1

Stock Incentive Plans (Detail Textuals 1) (USD $)	3 Months Ended
	Mar. 31, 2015
Stock Incentive Plans [Abstract]
Unrecognized compensation cost related to unvested stock options	$750,000
Unrecognized compensation cost related to unvested stock options, recognition period	2 years 2 months 12 days
Intrinsic value of options outstanding	0
Intrinsic value of options exercisable	$0
Options outstanding exercise price	$0.58

Intellectual_Property_and_Coll1

Intellectual Property and Collaborative Agreements (Detail Textuals) (Novosom, December 2014 license agreement with MiNA Therapeutics, USD $)	1 Months Ended
Share data in Millions, unless otherwise specified	Jan. 31, 2015
Novosom | December 2014 license agreement with MiNA Therapeutics
Intellectual Property And Collaborative Agreements [Line Items]
Cash payable	$80,000
Number of common stock issued for settlement	0.12
Amount pledged to issue common stock	$75,000

Subsequent_Events_Detail_Textu

Subsequent Events (Detail Textuals) (Subsequent event, Amended December 2011 with Mirna Therapeutics, Inc., USD $)	1 Months Ended
	11-May-15
Subsequent event | Amended December 2011 with Mirna Therapeutics, Inc.
Subsequent Event [Line Items]
Payment For Future Milestone Obligation	$400,000